STOCK TITAN

[Form 4] Nuvalent, Inc. Insider Trading Activity

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Nuvalent (NUVL) reported insider activity by its Chief Legal Officer on 10/30/2025. The officer exercised 21,800 stock options at an exercise price of $6.89 and sold an equal 21,800 Class A shares in multiple same‑day open‑market transactions with weighted average prices disclosed for each tranche.

Tranche prices reported include weighted averages of $96.65, $97.98, $99.66, $100.96, $102.00, $102.88, $103.90, and $104.78. Following the transactions, the officer directly owned 49,086 shares. The filing notes the trades were effected under a Rule 10b5-1 plan adopted on November 18, 2024, and the option exercised was fully vested; 118,808 derivative securities were beneficially owned after the transactions.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Miller Deborah Ann

(Last) (First) (Middle)
C/O NUVALENT, INC.
ONE BROADWAY, 14TH FLOOR

(Street)
CAMBRIDGE MA 02142

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Nuvalent, Inc. [ NUVL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 10/30/2025 M(1) 21,800 A $6.89 70,886 D
Class A Common Stock 10/30/2025 S(1) 700 D $96.65(2) 70,186 D
Class A Common Stock 10/30/2025 S(1) 1,273 D $97.98(3) 68,913 D
Class A Common Stock 10/30/2025 S(1) 500 D $99.66(4) 68,413 D
Class A Common Stock 10/30/2025 S(1) 600 D $100.96(5) 67,813 D
Class A Common Stock 10/30/2025 S(1) 2,121 D $102(6) 65,692 D
Class A Common Stock 10/30/2025 S(1) 3,733 D $102.88(7) 61,959 D
Class A Common Stock 10/30/2025 S(1) 3,491 D $103.9(8) 58,468 D
Class A Common Stock 10/30/2025 S(1) 9,382 D $104.78(9) 49,086 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $6.89 10/30/2025 M(1) 21,800 (10) 04/29/2031 Class A Common Stock 21,800 $0 118,808 D
Explanation of Responses:
1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.50 to $96.96, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (9) of this Form 4.
3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.70 to $98.08, inclusive.
4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.36 to $100.25, inclusive.
5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.42 to $101.38, inclusive.
6. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.42 to $102.40, inclusive.
7. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.42 to $103.40, inclusive.
8. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.43 to $104.42, inclusive.
9. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.45 to $104.85, inclusive.
10. The shares underlying this option are fully vested.
/s/ Nathan McConarty, attorney-in-fact 10/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Nuvalent, Inc.

NASDAQ:NUVL

NUVL Rankings

NUVL Latest News

NUVL Latest SEC Filings

NUVL Stock Data

8.24B
74.46M
2.84%
109.13%
7.61%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE